Cwm LLC Lowers Holdings in ADMA Biologics Inc $ADMA

Cwm LLC decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,572 shares of the biotechnology company’s stock after selling 1,081 shares during the quarter. Cwm LLC’s holdings in ADMA Biologics were worth $320,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new position in ADMA Biologics during the 1st quarter worth about $35,000. SVB Wealth LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $35,000. Toth Financial Advisory Corp boosted its stake in shares of ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 2,293 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in ADMA Biologics during the second quarter valued at approximately $46,000. Finally, Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,493 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 0.5%

NASDAQ ADMA opened at $15.18 on Monday. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a 50 day moving average price of $15.81 and a 200 day moving average price of $18.24. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.62 billion, a PE ratio of 17.65 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 earnings per share. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.